Drug-induced depression

Psychotherapy and Psychosomatics

Volumn 66, Issue 2, 1997, Pages 63-73

  Patten, Scott B ^a   Love, Edgar J ^b  

^a ALBERTA ENVIRONMENT AND PARKS   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adverse drug reactions; Calcium channel blockers; Chemically induced; Depressive disorder; Digoxin Side effects; Epidemiology; Steroid hormones

Indexed keywords

ALPHA INTERFERON; ANTILIPEMIC AGENT; BACLOFEN; BROMPHENIRAMINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARBARIL; CHOLINE; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETRETINATE; FLUOROURACIL; HORMONE; HYPNOTIC AGENT; ISOTRETINOIN; LOMEFLOXACIN; MEFLOQUINE; METOCLOPRAMIDE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PHENYTOIN; PHYSOSTIGMINE; PSYCHOSTIMULANT AGENT; RETINOIC ACID; SEDATIVE AGENT; SUMATRIPTAN; UNINDEXED DRUG; VIGABATRIN;

ARTICLE; DEPRESSION; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN;

EID: 0030972328     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000289110     Document Type: Article

References (165)

1. Cornelius JR, Fabrega H, Mezzich J, Cornelius MD, Ulrich RG: Characterizing organic mood syndrome, depressed type, Compr Psychiatry 1993:34:432-440.
2. Fogel BS: Major depression versus organic-mood disorder: A questionable distinction, J Clin Psychiatry 1990:51:53-56.
3. Steiner ML, Dukes MNG, Bceley L (eds): Myl-er's Side Effects of Drugs Annual 13, Amsterdam, Elsevier, 1989, pp 173-182.
4. Elliott HL, Dukes MNG (eds): Myler’s Side-Effects of Drugs, ed 12, Amsterdam, Elsevier, 1992, pp 478-490.
5. Patterson JF: Depression associated with cnal-april, South Med J 1989:82:402-403.
6. Hallas J: Evidence of depression provoked by-card iovascular medications: A prescription sequence symmetry analysis, Epidemiology 1996:7:478-484.
7. Patten SB, Williams JVA, Love EJ: Cardiovascular medications as risk factors for clinically diagnosed depressive disorders in an inpatient population: A case-control study, Can J Psychiatry, in press.
8. Heal DJ, Butler SA, Hurst EM, Buckett WR: Antidepressant treatments, including sibu-tramine hydrochloride and electroconvulsive shock, decrease pi-but not p-adrenoceptors in rat cortex, J Neurochem 1989:53:1019-1025.
9. Sellinger-Barnett MM, Mendels J, Frazer A: The effect of psychotropic drugs on beta-adrenergic receptor binding in rat brain, Neuropharmacology 1980:19:447-454.
10. Aarons RD, Molinoff PB: Changes in the density of beta-adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol, J Pharmacol Ther 1982:221: 439-443.
11. Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB: Elevation of p-adrenergic receptor density in human lymphocytes after propranolol administration, J Clin Invest 1980:65: 949-957.
12. Tang SW, Remington G, Persad E, Rosenblat R: Coadministration of a beta-adrenergic antagonist and a tricyclic antidepressant: A pilot study, Psychiatry Res 1990:33:101-106.
13. Kalayam B, Shamoian CA: Propranolol, psy-choneuroendocrinc changes, and depression, Am J Psychiatry 1982:139:1374-1375.
14. Pollack MH, Rosenbaum JF, Cassenr NH: Propranolol and depression revisited: Three cases and a review, J Nerv Ment Dis 1985:173:118-119.
15. Cremona-Barbaro A: Propranolol and depression, Lancet 1983:1:185.
16. Russell JW, Schuckit M A: Anxiety and depression in patient on nadolol, Lancet 1982:Vol ii: 1982-1983.
17. McNeil GN, Shaw PK, Dock DS: Substitution of atenolol for propranolol in a case of propran-olol-rclatcd depression, Am J Psychiatry 1982; 139:1187-1188.
18. Oppcnheim G: Propranolol-induced depression: Mechanism and management, Aust NZ J Psychiatry 1983:17:400-402.
19. Yudofsky SC: p-Blockers and depression, The clinician's dilemma, JAMA 1992:267:1826-1827.
20. Adler L: CNS effects of beta blockade: A comparative study, Psychopharmacol Bull 1988: 24:232-237.
21. Fodor JG, C'ockalingam A, Drover A, Fiftcld F, Pauls CJ: A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension, J Clin Pharmacol 1987;27:892-901.
22. Roa MR, O'Brien J, Dening TR, Dober M: Systemic hazard of ocular timolol, Br J Hosp Med 1993:50:553.
23. Nolan BT: Acute suicidal depression associated with use of timolol, JAMA 1982:247:1567.
24. Duch S, Duch C, Pasto L, Ferrer P: Changes in depressive status associated with topical beta-blockers, Int Ophthalmol 1992:16:331-335.
25. 125l-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments, J Pharmacol Exp Ther 1991:257:681-690.
26. Ordway GA, Gambarana C, Frazer A: Quantitative autoradiography of central beta adrenoceptor subtypes: Comparison of the effects of chronic treatment with desipraminc or centrally administered l-isoproterenol, J Pharmacol Exp Ther 1988;247:379-389.
27. Minneman KP, Dibncr MD, Wolff BB, Molinoff PB: Pi-and Pi-Adrenergic receptors in rat cerebral cortex are independently regulated, Science 1979;204:866-868.
28. Griffin SJ, Friedman MJ: Depressive symptoms in propranolol users, J Clin Psychiatry 1986:47:453-457.
29. Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U: Increased prescribing of antidepressants subsequent to p-blockcr therapy, Arch Intern Med 1990:150:2286-2290.
30. Avorn J, Everitt DE, Weiss S: Increased antidepressant use in patients prescribed p-blockcrs, JAMA 1986:255:357-360.
31. Isacson D, Bingefors K, Carlson G: Analysing psychiatric side-effects of beta-blockers using large computerized data bases, Pharmacocpi-demiol Drug Safety 1995:4:335-341.
32. Bright RA, Everitt DE: P-Blockers and depression, Evidence against an association, JAMA 1992;267:1783-1787.
33. Goble AJ: p-Blocker treatment and depression, Arch Intern Med 1992:152:649.
34. Patten SB: Can drug-induced depressions be identified by their clinical features? Can J Psychiatry 1992:37:213-215.
35. Binstock G, Foster LG, Mullane JF: Propranolol and the depression component of anxiety neurosis, CurrThcr Res 1984:35:423-432.
36. Sorgi P, Ratey J, Knoedler D, Arnold W, Cole L: Depression during treatment with beta-blockers: Results from a double-blind placebo-controlled study, J Neuropsychiatry Clin Neu-rosci 1992;4:187-189.
37. Kostis J B, Rosen RC, Holzer BC, Randolph C, Taska LS, Miller MH: CNS side effects ofccn-trally-active antihypertensive agents: A prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males, Psychopharmacology 1990:102:163-170.
38. Stoudcmire A, Brown JT, Harris RT, Blessing-Feussner C, Roberts JH, Nichols JC, Houpt JL: Propranolol and depression: A réévaluation based on a pilot clinical trial, Psychiatr Med 1984;2:211-218.
39. Schlefer SJ, Slater WR, Macari-Hinson MM, Coyle DA, Kahn M, Zucker HD, Gorlin R: Digitalis and p-blocking agents: Effects on depression following myocardial infarction, Am Heart J 1991:121:1397-1402.
40. Carney RM, Rich MW, teVelde A, Saini J, Clark K, Freedland KE: Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications, Am J Med 1987:83:223-226.
41. Bartels D, Glasser M, Wang A, Swanson P: Association between depression and propranolol use in ambulatory patients, Clin Pharm 1988;7:146-150.
42. Hullet FJ, Potkin SG, Levy AB, Ciasca R: Depression associated with nifedipine-induced calcium channel blockade, Am J Psychiatry' 1988;145:1277-1279.
43. Eccleston D, Cole AJ: Calcium-channel blockade and depressive illness, Br J Psychiatry 1990:156:889-891.
44. Dassylva B: Verapamil may cause depression, Can j Psychiatry 1993;38:299-300.
45. Fogclman J: Verapamil caused depression, confusion, and impotence, Am J Psychiatry 1988:145:380.
46. Biriell C, McEwan J, Sanz E: Depression associated with diltiazem, Br Med J 1989:299:796.
47. Govoni S, Battaini F, Magnoni MS, Trabucchi M: Non-vascular central nervous system effects of calcium entry blockers, Cephalalgia 1985 (suppl 2):115-118.
48. Pardal MF, Pardal JF, Micheli F: Aggravation of Parkinson's disease by cinnarizine, J Neurol Ncurosurg Psychiatry 1988:51:158-159.
49. 2*], in rat cerebral synaptosomes and hippocampal neurons, Jpn J Pharmacol 1992.58: 417-425.
50. Takada M, Kono T, Kitai ST: Flunarizine induces a transient loss of tyrosine hydroxylase immunorcactivity in nigrostriatal neurons, Brain Res 1992;590:311-315.
51. Ambrosio C, Stefanini E: Interaction of flunarizine with dopamine D? and D1 receptors, Eur J Pharmacol 1991;197:221-223.
52. Ikegami A, Ozaki A, Hara H, Sukamoto T, Yamashita A, Ito K: Neurochemical investigation on the effects of a new diphenylpiperazine calcium channel antagonist, KB-2796, on the central dopaminergic system of rats, Jpn J Pharmacol 1992:58:399-405.
53. Micheli F, Pardal MF, Gallo M, Torres M, Paradiso G, Parera IC, Giannaula R: Flunari-zine-and cinnarizinc-induccd extrapyramidal reactions, Neurology 1987;37:881-884.
54. Capclla D, Importe JR, Castel JM, Tristan C, Cos A, Morales-Olivas FJ: Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine, Br Med J 1988:297:722-723.
55. Micheli FE, Pardal MF, Giannaula R, Gallo M, Parera IC, Paradiso G, Torres M, Pikielny R, Pardal JF: Movement disorders and depression due to flunarizine and cinnarizine, Mov Disord 1989:4:139-146.
56. Lugaresi A, Montagna P, Gallassi R, Lugarcsi E: Extrapyramidal syndrome and depression induced by flunarizine, Eur Neurol 1988:28: 208-211.
57. D'Alessandro R, Benassi G, Morganti G: Side-effects of flunarizine, Lancet 1986:Vol ii:463.
58. Gawel MJ, Krecfl J, Simard ND, Amott WS: Comparison of the efficacy and safety of flu-narizinc to propranolol in the prophylaxis of migraine, Can J Neurol Sci 1992:19:340-345.
59. Sorensen PS, Larsen BH, Rasmussen MJ, King E, Ivcrscn H, Alslev T, Nohr P, Pedersen KK: Flunarizine versus metoprolol in migraine prophylaxis: A double-blind, randomized parallel group study of efficacy and tolerability, Headache 1991:10:650-657.
60. Patten SB, Thompson J: Organic depression associated with flunarizine, Can J Psychiatry 1995:40:111-112.
61. Dubrovsky B: Effects of adrenal cortex hormones on limbic structures: Some experimental and clinical correlations related to depression, J Psychiatr Neurosci 1993:18:4-16.
62. Grigg JR: Prednisone mood disorder with associated catatonia, J Geriatr Psychiatry Neurol 1989;2:41-44.
63. Gift AG, Wood RM, Cahill CA: Depression, somatization and steroid use in chronic obstructive pulmonary disease, Int J Nurs Stud 1989:26:281-286.
64. Patten SB, Williams JVA, Love F.J: Self-reported depressive symptoms in association with medication exposures among medical inpatients: A cross-sectional study, Can J Psychiatry 1995:40:264-269.
65. Patten SB, Williams JVA, Love EJ: Self-reported depressive symptoms following treatment with corticosteroids and sedative-hypnotics, int J Psychiatr Med 1996:26:15-24.
66. Patten SB, Williams JVA, Love EJ: A case-control study of corticosteroid exposure as a risk factor for clinically-diagnosed depressive disorders in a hospitalized population, Can J Psychiatry 1995:40:396-400.
67. Boston Collaborative Drug Surveillance Program: Acute adverse reactions to prednisone in relation to dosage, Clin Pharm Ther 1972:13: 694-698.
68. El-Mallakh RS, Hedges S, Casey D: Digoxin encephalopathy presenting as mood disturbance, J Clin Psychopharmacol 1995; 15:82-83.
69. Wamboldt FS, Jefferson JW, Wamboldt MZ: Digitalis intoxication misdiagnosed as depression by primary care physicians, Am J Psychiatry 1986:143:219-221.
70. Palinkas LA, Wingard DL, Barrett-Connor E: Chronic illness and depressive symptoms in the elderly: A population-based study, J Clin Epidemiol 1990:43:1131-1141.
71. Okada F: Depression alter treatment with thiazide diuretics for hypertension, Am J Psychiatry 1985:142:1101-1102.
72. Thaler L, Wassertheil-Smollcr S, Blaufox MD, Obcrman A, Langford HG: Elfect of withdrawal of antihypertensive drug on depressive mood, Am J Hypertens 1993:6:1055-1062.
73. Applegate WB, Pressel S, Wittes J, Luhr J, She-kclie RB, Camel GH, Grccnlick MR, Hadley E, Move L, Perry HM, et al: Impact of the treatment of isolated systolic hypertension on behavioral variables, Results from the Systolic Hypertension in the Elderly Program, Arch Intern Med 1994:154:2154-2160.
74. Crowder MK, Pate K: A case-report of cimcti-dine-induced depressive syndrome, Am J Psychiatry 1980:137:1451.
75. Pierce JR: Case report, Cimetidine-associated depression and loss of lbido in a woman, Am J Med Sci 1983:286:31-34.
76. Billings RF, Stein MB: Depression associated with ranitidine, Am J Psychiatry 1986:143: 915-916.
77. Porter JB, Beard K, Walker AM, Lawson DH, Jick H, Kellaway GSM: Intensive hospital monitoring study of intravenous cimetidinc, Arch Intent Med 1986:146:2237-2239.
78. Gifford LM, Acuglc ME, Mycrson RM, Tannenbaum PJ: Cimetidine postmarket outpatient surveillance program, Interim report on phase I, JAMA 1980;243:1532-1535.
79. Robins AH, McFadyen ML, Lucke W, Wright JP: Effect of the IT-rcceptor antagonist ranitidine on depression and anxiety in duodenal ulcer patients, Postgrad Med J 1984:60:353-355.
80. Patten SB, Williams JVA, Love EJ: IT blocker exposure as a risk factor for depression, Can J Psychiatry 1996:41:537-538.
81. Wagner KD, Berenson AB: Norplant-associated major depression and panic disorder, J Clin Psychiatry 1994;55:478-480.
82. Wagner KD: Major depression and anxiety disorders associated with Norplant, J Clin Psychiatry 1996:57:152-157.
83. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, Washington, American Psychiatric Association, 1994.
84. Westhoff C, Wieland D, Ticzzi L: Depression in users of depo-medroxyprogesterone acetate, Contraception 1995:51:351-354.
85. Herzberg BN, Johnson AL, Brown S: Depressive symptoms and oral contraceptives, Br Med J 1970;Vol iv:142-145.
86. Nilson A, Almgrcn PE: Psychiatric symptoms during the post-panum period as related to use of oral contraceptives, Br Med J 1968:Vol ii:453-455.
87. Lecton J, Lcinkram C, Stiglitz J: The relationship of oral contraception to depression, Aust N Z J Obstet Gynaecol 1971:11:237-240.
88. Fleming O, Seager CP: Incidence of depressive symptoms in users of the oral contraceptive, BrJ Psychiatry 1978;132:431-440.
89. Adams PW, Rose DP, Folkard J, Wynn V, Seed M, Strong R: Effect of pyridoxinc hydrochloride (vitamin B) upon depression associated with oral contraception, Lancet 1973:Vol i: 897-904.
90. Kay CR: The Royal College of General Practitioners’ Oral Contraception Study: Some recent observations, Clin Obstet Gynaecol 1984:11:759-786.
91. Rosenblatt DE, Mellow A: Depression during hormonal treatment of prostate cancer, J Am Board Fam Pract 1995:8:317-320.
92. Love RR: Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects, J Clin Oncol 1989:7:803-815.
93. Sharin S, C’umming CE, Lces A, Handman VI, Cumming DC: Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist, An expected or unexpected effect? Ann NY Acad Sci 1995: 761:365-368.
94. Morcdo TF, Anclli A, Tran K, Lebwohl DE, Borgen PI: Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients, Cancer 1994:74:74-77.
95. Love RR, Cameron L, Connell BL, Leventhal H: Symptoms associated with tamoxifen treatment in postmenopausal women, Arch Intern Med 1996;151:1842-1847.
96. Duits N, Bos FM: Depressive symptoms and cholesterol-lowering drugs, Lancet 1993:341: 114.
97. Leehleitncr M, Hoppichlcr F, Konwalinka G, Patsch JR, Braunsteiner H: Depressive symptoms in hypercholesterolemic patients treated with pravistatin, Lancet 1992:340:910.
98. Boumendil E, Tubert-Bitter P: Depression-induced absenteeism in relation to antihy-pcrlipidcmic treatment: A study using GAZEL cohort data, Epidemiology 1995;6:322-325.
99. Ernst E, Saradeth T, Seidl S, Resch KL, Fri-schenschlagcr O: Cholesterol and depression, Arch Intern Med 1994; 154:1166.
100. Engelberg H: Low serum cholesterol and suicide, Lancet 1992:339:727-728.
101. Cclcsia GG, Barr AN: Psychosis and other psychiatric manifestations of levodopa therapy, Arch Neurol 1970:23:193-200.
102. Yzrvura-Tobias JA, Diamond B, Merlis S: Psychiatric manifestations of levodopa, Can Med Assoc J 1972:17:SS123-SS128.
103. Mindham RHS, Marsden CD, Parkes JD: Psychiatric symptoms during /-dopa therapy for Parkinson’s disease and their relationship to physical disability, Psychol Med 1976:6: 23-33.
104. Maricle RA, Nutt JG, Carter JH: Mood and anxiety fluctuation in Parkinson’s disease associated with levodopa infusion: Preliminary findings, Mov Disord 1995; 10:329-332.
105. Cummings JL: Depression and Parkinson's disease: A review, Am J Psychiatry 1992:149: 443-454.
106. Gotham AM, Brown RG, Marsdcn CD: Depression in Parkinson’s disease: A quantitative and qualitative analysis, J Neurol Neuro-surg Psychiatry 1996:49:381-389.
107. Haleem DJ, Yasmeen A, Halcem MA, Zafar A: 24 h withdrawal following repeated administration of caffeine attenuates brain serotonin but not tryptophan in rat brain: Implications for caffeine-induced depression, Life Sei 1995:57:285-292.
108. Siverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption, N Engl J Med 1992:327:1109-1114.
109. Wnokur B, Lcsscnt P: Caffeine withdrawal, metoclopramide, and depression, Am J Gastroenterol 1993:88:1464.
110. Gredcn JF, Fontaine P, Lubctsky M, Chamberlin K: Anxiety and depression associated with caffeinism among psychiatric inpatients, Am J Psychiatry 1978:135:963-966.
111. James JE, Crosbic J: Somatic and psychological health implications of heavy caffeine use, BrJ Addict 1987;82:503-509.
112. Jacobsen BK, Hansen V: Caffeine and health, BrMcdJ 1988:296:291.
113. Mino Y, Yasuda N, Fujimura T, Ohara H: Caffeine consumption and anxiety and depressive symptomatology among medical students, Jpn J Drug Alcohol Depend 1990:25: 486-496.
114. Mayo KM, Falkowski W, Jones CAH: Caffeine: Use and clfects in long-stay psychiatric patients, BrJ Psychiatry 1993:162:543-545.
115. Brown RT, Borden KA, Spunt AL, Medcnis R: Depression following pemoline withdrawal in a hyperactive child, Clin Pediatr 1985: 24:174.
116. Harding T: Fenfluramine dependence, Br Med J 1971 :Vol iii:305.
117. Harding T: Depression following fenfluramine withdrawal, Br J Psychiatry 1972:121: 338-339.
118. Steele JM, Briggs M: Withdrawal depression in obese patients after fenfluramine treatment, Br Med J 1972:Vol iii:26-27.
119. Tuma TA: Depressive stupor following amphetamine withdrawal, BrJ Hosp Pracl 1993: 49:361-363.
120. Halle MT, Dilsaver SC: Tranylcypromine w ithdrawal phenomena, J Psychiatr Neurosci 1993:18:49-50.
121. Farmer P, Unis AS, HsuG: Pemoline, depressive symptoms, and escape from déxaméthasone suppression, J Clin Psychopharmacol 1983:3:331-332.
122. Twerski B: Sympathomimetic-induced depression, Am J Psychiatry 1987:144:252.
123. Grigg JR, Goyer PF: Phenylpropanolamine anorexiants and affective disorders, Milit Med 1986:151:387-388.
124. Rihmcr Z, Rêvai K, Arato M, Pcrcnyi A: Two case reports of mazindol-induced depression, Am J Psychiatry 1984:141:1497-1498.
125. Edwards JG, Inman WHW, Pearce GL, Raw-son NSB: Prescription-event monitoring of 10.895 patients treated with alprazolam, BrJ Psychiatry 1991:158:387-392.
126. Buckner JC, Mandell W: Risk factors for depressive symptomatology in a drug using population, Am J Publ Health 1990:80:580-585.
127. Hall RCW, Joffe JR: Aberrant response to diazepam: A new syndrome, Am J Psychiatry 1972;129:114-118
128. Hall RCW, Zisook S: Paradoxical reactions to benzodiazepines, BrJ Clin Pharmacol 1981: 99S-104S.
129. Olajide ML, Lader M: Depression following withdrawal from long-term benzodiazepine use: A report of four cases, Psychol Med 1984: 14:937-940.
130. Lader M: Anxiety or depression during withdrawal of hypnotic treatments, J Psychosom Res 1994:38:113-123.
131. Benichou C, Bcnichou C (cds): Adverse Drug Reactions, A Practical Guide to Diagnosis and Management, Chichester, Wiley, 1994, pp xiii-xv.
132. Benichou C, Danan G, Benichou C (eds): Adverse Drug Reactions, A Practical Guide to Diagnosis and Management, Chichester, Wiley, 1994, pp 277-283.
133. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, Washington, American Psychiatric Association, 1987.
134. Rothman KJ: Causes, Am J Epidemiol 1976; 104:587-592.
135. Sommer BR, Pctridcs G: A case of baclofen-induced psychotic depression, J Clin Psychiatry 1992:536:211-212.
136. Kavanagh GM, Charlwood MR, Peachey RD: Withdrawal symptoms after discontinuation of long-acting brompheniramine male-ale, BrJ Dermatol 1994:131:913.
137. Gardner DL, Cowdry RW: Development of melancholia during carbamazepine treatment in borderline personality disorder, J Clin Psychopharmacol 1986:6:236-239.
138. Weiner PK, Young RC: Late-onset psychotic depression associated with carbaryl exposure, Am J Psychiatry 1995:152:646-647.
139. Tamminga C, Smith RC, Chang S, Haraszti JS, Davis JM: Depression associated with oral choline, Lancet 1976; 1:905.
140. Hazen PG, Carney JF, Walker AE, Stewart J J: Depression-a side effect of 13-ifv-retinoic acid therapy, J Am Acad Dermatol 1983:9: 278-279.
141. Henderson CA, Highet AS: Depression induced by etretinate, BMJ 1989:298:964.
142. Miistein MG: Mental depression secondary to fluorouracil therapy for actinic keratoses, Arch Dermatol 1980; 116:1100.
143. Bjorkman A: Acute psychosis following mefloquine prophylaxis, Lancet 1989;Vol ii:865.
144. Weinke T, Trautman M, Held T, Weber G, Eichenlaub D, Fleischer K, Kcm G, Pohlc HD: Neuropsychiatrie side effects after the use of mefloquine, Am J Trop Med Hyg 1991; 45:86-91.
145. Adams CD: Metoclopramide and depression, Ann Intern Med 1985:103:960.
146. Feder R: Metoclopramide and depression, J Clin Psychiatry 1987:48:38.
147. Giannini AJ: Side effects of metronidazole, Am J Psychiatry 1977:134:329-330.
148. Von AJ: Possible association between metronidazole and agitated depression, Can Med Assoc J 1969:100:1012-1013.
149. Meyers CA, Scheibcl RS, Forman AD: Persistent neurotoxicity of systemicaliy administered interferon-alpha, Neurology 1991:41: 672-676.
150. Merimsky O, Reider-Groswasscr I, Inbar M, Chaitchik S: Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma, EurJ Cancer 1990; 26:596-600.
151. Thomas MA, Ibanez HE: Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization, Am J Ophthalmol 1993:115: 563-568.
152. Renault PF, Hoofnaglc JH, Park Y, Mullen KD, Peters M, Joncs B, Rustgi V, Jones A: Psychiatric complications of long-term interferon alfa therapy, Arch Intern Med 1987: 147:1577-1580.
153. Gatti S, Serri F: Acute depression from isotretinoin, J Am Acad Dermatol 1991;25:132.
154. Byme A, Hnatko G: Depression associated with isotretinoin therapy, Can J Psychiatry 1995:40:567.
155. Sheinman PL, Peck GL, Rubinow DR, Di-Giovanna JJ, Abangan DL, Ravin PD: Acute depression from isotretinoin, J Am Acad Dermatol 1990:6:1112-1113.
156. Feinberg SS: Flouroquinolonc-induced depression, Am J Psychiatry 1995,152:954-955.
157. Blechman WJ, Schmid FR, April PA, Wilson CH, Brooks CD: Ibuprofen or aspirin in rheumatoid arthritis therapy, JAMA 1975:233: 336-339.
158. Cochrane GM: A double-blind comparison of naproxen with indomethacin in osteoarthritis, Scand J Rheumatol 1973;2(suppl):89-93.
159. Oren DA: Dysphoria after treatment with ondansetron, Am J Psychiatry 1995:152:1101.
160. Garrison SJ, Henson HK: Dilantin toxicity and vegetative depression: A report of two cases, Arch Phys Med Rehabil 1990:71:422-423.
161. Janowsky DS, El-Yousef K, Davis JM, Se-kerke HJ: Parasympathetic suppression of manic symptoms by physostigmine, Arch Gen Psychiatry 1973:28:542-547.
162. LaPorta LD: Recurrent depression after sumatriptan administration for treatment of migraine, J Clin Psychopharmacol 1995;15: 81-82.
163. Murphy MB, Dillon A, Fitzgerald MX: Theophylline and depression, Br Med J 1980: 281:1322.
164. Bernstein AL, Leventhal-Rochon JL: Neurotoxicity related to the use of topical tretinoin, Ann Intern Med 1996:124:227-228.
165. Ring HA, Crellin R, Kirker S, Reynolds EH: Vigabatrin and depression, J Neurol Neuro-surg Psychiatry 1993:56:925-928.